Here, we showed that anti-EGFR nimotuzumab (domain III) did not alter the in vitro binding (Figure 2) and tumor uptake in vivo (Figure 5 and Figure S4) of anti-EGFR 89Zr-8709-scFv-Fc. The gene discussed is EGFR; the disease is neoplasm.